Initial Treatment for Heartburn in Urgent Care

First-Line Therapy

The American Gastroenterological Association recommends starting with a proton pump inhibitor (PPI) at standard dose once daily for 4-8 weeks as first-line therapy for patients presenting with heartburn without alarm symptoms 1, 2, 3
PPIs provide significantly faster and more complete symptomatic relief compared to H2-receptor antagonists, with omeprazole 20 mg once daily taken before meals being the most effective initial therapy 3

The American College of Gastroenterology suggests avoiding lying down for 2-3 hours after meals to reduce esophageal acid exposure 3, 4
Elevating the head of the bed is recommended for patients with nighttime symptoms or regurgitation when recumbent 3, 4
Weight loss is recommended for overweight or obese patients, as this directly improves GERD symptoms 3
Avoiding trigger foods on an individualized basis, such as coffee, chocolate, alcohol, spicy foods, citrus, and tomatoes, is suggested if these consistently worsen symptoms 3

If symptoms persist despite once-daily PPI after 4-8 weeks, increasing to twice-daily dosing (omeprazole 20 mg twice daily before meals) is recommended 1, 2, 3
Doubling the dose of H2-receptor antagonists like ranitidine is not efficacious, with less than 20% of patients achieving complete heartburn resolution with this approach

The American College of Gastroenterology recommends referring for endoscopy if alarm symptoms are present (dysphagia, odynophagia, weight loss, GI bleeding, anemia) 1, 2
Symptoms not responding adequately to twice-daily PPI after 4-8 weeks, or patients requiring long-term PPI therapy without confirmed diagnosis, also require endoscopy 2
Patients over 50 years with new-onset symptoms should be referred for endoscopy 2

Extraesophageal symptoms, such as chronic cough or hoarseness, require more intensive therapy with twice-daily PPI for 8-12 weeks minimum 3
Response rates are lower for extraesophageal symptoms compared to typical heartburn, and 1-3 months may be needed to assess response before considering treatment failure 3
The American Gastroenterological Association emphasizes the safety of PPIs for GERD treatment, and periodic reassessment of the need for continued therapy is recommended to minimize potential long-term risks 1, 3